Commentary Open Access
Selenium-modified natural polysaccharides: bridging preclinical antioxidant mechanisms to clinical translation in hepatic fibrosis and related gastroenterological disorders
Yuwen Wang1,2,3, Junfeng Niu1,2,3,*
- 1National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest China, Shaanxi Normal University, Xi’an 710119, China
- 2Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry (Shaanxi Normal University), The Ministry of Education, Xi’an 710119, China
- 3College of Life Sciences, Shaanxi Normal University, Xi’an 710119, China
Corresponding Author
Junfeng Niu, niujunfeng@snnu.edu.cn
Received Date: March 10, 2026
Accepted Date: March 27, 2026
Wang Y, Niu J. Selenium-modified natural polysaccharides: bridging preclinical antioxidant mechanisms to clinical translation in hepatic fibrosis and related gastroenterological disorders. J Clin Exp Gastroenterol. 2026;5(1):15–22.
Copyright: © 2026 Wang Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
From molecular mechanisms to precision medicine: Transformative approaches in cirrhosis management
The rising prevalence of cirrhosis has become a significant global health concern. Cirrhosis is a leading cause of morbidity and mortality worldwide, contributing to a substantial burden on healthcare systems and economies.
Selenium-modified natural polysaccharides: bridging preclinical antioxidant mechanisms to clinical translation in hepatic fibrosis and related gastroenterological disorders
Liver fibrosis represents a critical convergence point in gastroenterological practice, serving as the common pathway from chronic injury—whether metabolic (MASLD/MASH), alcoholic, viral, or drug-induced—to cirrhosis and hepatocellular carcinoma. Globally, cirrhosis and chronic liver disease account for over 1.5 million deaths annually, with MASLD now the leading indication for liver transplantation in many regions.
Carvedilol and the evolving management of portal hypertension in compensated cirrhosis
Cirrhosis remains a major cause of liver-related mortality worldwide. The transition from compensated to decompensated disease, marked by complications such as ascites, hepatic encephalopathy, or variceal hemorrhage represents a critical shift in prognosis and survival. Clinically significant portal hypertension (CSPH) is the primary driver of this progression, making portal pressure reduction a central therapeutic target.